Home › Metastatic Cancer › NCT05530759

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

Integrated Genomics and Patient-Derived Cancer Models

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients (or the legally authorized representative/guardian signing on behalf of the participant) must understand and provide written informed consent prior to initiation of any study-specific procedures
* \>= 18 years of age
* Patients must have a diagnosis of confirmed malignancy
* Patient is a good medical candidate for a standard of care biopsy or surgical procedure to obtain tissue or has archival tissue available for analysis

Exclusion Criteria:

* Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
* Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use
* Biopsy must not be considered to be more than minimal risk to the patient. Contraindications to percutaneous biopsy:

  * Significant coagulopathy that cannot be adequately corrected
  * Severely compromised cardiopulmonary function or hemodynamic instability
  * Lack of a safe pathway to the lesion
  * Inability of the patient to cooperate with, or to be positioned for, the procedure

About the study

This study characterizes deoxyribonucleic acid (DNA) and proteomic (protein) changes in both biopsies and tumors removed during surgery of patients who have been diagnosed with aggressive/metastatic (that has spread to other places in the body) cancer in order to identify possible diagnostic markers and potential drugs for treating aggressive tumor types. Proteomic analyses include looking at the proteome, or all the proteins expressed, or made by DNA at a specific moment in time. Studying samples of blood, buccal (cheek), and tissue in the laboratory from patients undergoing surgical resection or biopsy may help doctors learn more about the changes that occur in the proteome, DNA alterations, and identify molecular biomarkers for which therapeutic drugs may exist. Studying the DNA in tumor tissue and in blood may also help researchers see if the tumor has important differences.

What is being tested

• Biopsy Specimen (procedure)
• Biospecimen Collection (procedure)
• Archived Biospecimen Collection (procedure)
• Medical Chart Review (other)

Sponsor: Mayo Clinic · Participants: 50 · Started: Jun 29, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05530759

Locations in the U.S.

Conditions

• Metastatic Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.